Brief: Medivir And SciLifeLab Enter Collaboration On Potential SARS CoV-2 Inhibitors

Medivir AB

06/07/2020 07:34

July 6 (Reuters) - Medivir AB  MVIRb.ST :
    * MEDIVIR AND SCILIFELAB ENTER COLLABORATION ON POTENTIAL
SARS
COV-2 INHIBITORS
    * DDD WILL GET ACCESS TO MEDIVIR'S UNIQUE PROPRIETARY
PROTEASE-TARGETED COMPOUND LIBRARY.
    * THROUGH COLLABORATION, DDD WILL GET ACCESS TO MEDIVIR'S
UNIQUE
PROPRIETARY PROTEASE-TARGETED COMPOUND LIBRARY.
    * RESEARCH COLLABORATION WITH DRUG DISCOVERY AND DEVELOPMENT
PLATFORM (DDD) AT SCILIFELAB ON POTENTIAL INHIBITORS OF SARS
COV-2.
    * AIM OF COLLABORATION IS TO FIND POTENTIAL INHIBITORS OF
MAIN
PROTEASE OF SARS COV-2,
    * DATA FOR UP TO 100 TOP-INHIBITORS WILL BE RELEASED ON-LINE
AND
WILL BE FREELY AVAILABLE FOR DRUG DEVELOPMENT TO COMBAT COVID-19
    * PROJECT IS PART OF NATIONAL COVID-19 RESEARCH PROGRAM AT
SCILIFELAB, WHICH IS FUNDED BY KNUT AND ALICE WALLENBERG
FOUNDATION WITH A TOTAL OF 50 MSEK

Source text for Eikon:  ID:nWkr9m5LQJ 
Further company coverage:  MVIRb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587785110;))